Key result
Carriers of putative cLQTS genetic variants showed no significant difference in syncope (1.8% vs 1.6%, P=0.80) or overall mortality (3.2% vs 4.7%, P=0.24) compared with non-carriers.
Why the study?
Do rare genetic variants previously associated with congenital long QT syndrome affect the QTc interval, syncope propensity, or mortality in a general population?
Cohort (n=7,031)
Do rare genetic variants previously associated with congenital long QT syndrome affect the QTc interval, syncope propensity, or mortality in a general population?
Absolute Event Rate: 1.8% vs 1.6%
p-value: p=0.80
Several genetic variants previously associated with congenital long QT syndrome show no effect on QTc interval, syncope, or mortality in a general population, suggesting they are unlikely to cause dominant monogenic disease.
Questions pathogenicity of putative cLQTS variants in general populations; challenges monogenic causality and leaves open reclassification needs.
AIMS: We studied whether variants previously associated with congenital long QT syndrome (cLQTS) have an effect on the QTc interval in a Danish population sample. Furthermore, we assessed whether carriers of variants in cLQTS-associated genes are more prone to experience syncope compared with non-carriers and whether carriers have an increased mortality compared with non-carriers. METHODS AND RESULTS: All genetic variants previously associated with cLQTS were surveyed using the Human Gene Mutation Database. We screened a Danish population-based sample with available whole-exome sequencing data (n = 870) and genotype array data (n = 6161) for putative cLQTS genetic variants. In total, 33 of 1358 variants previously reported to associate with cLQTS were identified. Of these, 10 variants were found in 8 or more individuals. Electrocardiogram results showed normal mean QTc intervals in carriers compared with non-carriers. Syncope data analysis between variant and non-variant carriers showed that 4 of 227 (1.8%) and 95 of 5861 (1.6%) individuals, respectively, had experienced syncope during follow-up (P = 0.80). There was no significant difference in overall mortality rates between carriers [7/217 (3.2%)] and non-carriers [301/6453 (4.7%)] (P = 0.24). CONCLUSION: We present QTc data and register data, indicating that 26 cLQTS-associated variants neither had any effect on the QTc intervals nor on syncope propensity or overall mortality. Based on the frequency of individual gene variants, we suggest that the 10 variants frequently identified, assumed to relate to cLQTS, are less likely to associate with a dominant monogenic form of the disease.
No takes yet. Share an insight, caveat, or question.
Ghouse et al. (2015) conducted a cohort in Congenital long QT syndrome (cLQTS) (n=7,031). Putative cLQTS genetic variants vs. Non-carriers was evaluated on Syncope during follow-up (p=0.80). Carriers of putative cLQTS genetic variants showed no significant difference in syncope (1.8% vs 1.6%, P=0.80) or overall mortality (3.2% vs 4.7%, P=0.24) compared with non-carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: